Can a Low-Dose opioid curb suicidal urges in depression?
NCT ID NCT04116528
First seen Jun 01, 2026
Summary
This study tested whether taking buprenorphine (a low-dose opioid) after a ketamine infusion can reduce suicidal thoughts more quickly and effectively than ketamine alone in people with major depression. Fifty adults participated, and researchers measured changes in suicidal ideation over several weeks. The goal is to find a faster-acting treatment for suicide risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University School of Medicine
Stanford, California, 94305, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
buprenorphine
What this could lead to
If it works, this could point toward a faster way to reduce suicidal thoughts in people with major depression.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. Buprenorphine is an opioid and carries risks of dependence and side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.